医学
期限(时间)
移植
桥(图论)
重症监护医学
外科
天文
物理
标识
DOI:10.1016/j.ajt.2025.05.030
摘要
Intrahepatic cholangiocarcinoma (ICCA) represents an aggressive primary hepatic malignancy with a globally increasing incidence. While surgical resection offers a potential curative approach, the majority of patients are ineligible for surgery at the time of diagnosis, resulting in a generally poor prognosis. Recent advancements have been made in the management of unresectable ICCA, particularly through targeted therapies. Notably, the FGFR2 inhibitor pemigatinib has demonstrated significant efficacy in patients with tumors exhibiting FGFR2 fusion or rearrangement.
科研通智能强力驱动
Strongly Powered by AbleSci AI